MOVE vs MNMD vs AEYE

Analysts rate Movano Inc.

(MOVE) a "Buy" — based on 4 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Mind Medicine (MindMed) Inc.

(MNMD) delivered a total return of -58. 8%, compared to -98. 3% for Movano Inc. (MOVE). Over 10 years, the gap is even starker: MNMD returned +512. 1% versus MOVE's -98. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Mind Medicine (MindMed) Inc.

(MNMD) is the lower-risk stock at 1. 68β versus AudioEye, Inc. 's 2. 29β — meaning AEYE is approximately 36% more volatile than MNMD relative to the S&P 500. On balance sheet safety, Movano Inc. (MOVE) carries a lower debt/equity ratio of 3% versus 15% for AudioEye, Inc. — giving it more financial flexibility in a downturn.

On earnings-per-share growth, the picture is similar: Movano Inc.

grew EPS 38. 1% year-over-year, compared to -1273. 3% for Mind Medicine (MindMed) Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Mind Medicine (MindMed) Inc.

(MNMD) is the more profitable company, earning 0. 0% net margin versus -23. 4% for Movano Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MNMD leads at 0. 0% versus -23. 9% for MOVE. At the gross margin level — before operating expenses — AEYE leads at 78. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Mind Medicine (MindMed) Inc.

(MNMD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (+512. 1% 10Y return). Movano Inc. (MOVE) carries a higher beta of 1. 98 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (MNMD: +512. 1%, MOVE: -98. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (MOVE (Healthcare) and MNMD (Healthcare) and AEYE (Technology)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.